Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Corp.

www.mitsubishi.co.jp

Latest From Mitsubishi Corp.

Scrip 100: R&D Paths Of Top 50 Pharma

How has R&D spending in the pharmaceutical industry changed over the last decade? While the R&D collective picture for Big Pharma may not have changed much, individual company stories differ markedly.

Research & Development Research and Development Strategies

MerLion Preps Finafloxacin For Phase III As Advantages Confirmed

Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.

BioPharmaceutical Singapore

Deals Shaping the Medical Industry (04/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

AF Ablation: The Pulse of Innovation

The atrial fibrillation market has attracted the attention of a large number of established and emerging cardiovascular device companies over the past several years, all hoping to cash in on the huge demand for a simple, safe, and effective therapy that can permanently cure this common, and often debilitating, heart arrhythmia. Most of the research to date has focused on energy-based methods both surgical and percutaneous - to destroy aberrant electrical triggers in the heart that are believed to initiate and perpetuate AF. But no one has yet received FDA approval for a catheter-based ablation tool, a milestone that is widely recognized as key to full penetration of this market. To be sure, they have come close. But obtaining an FDA indication for the more complex AF ablation procedure has proven a much more difficult goal.
Medical Device
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Mitsubishi Corp.
  • Senior Management
  • Yorihiko Kojima, Pres. & CEO
  • Contact Info
  • Mitsubishi Corp.
    Phone: (81)
    6-3 Marunouchi 2-chome
    Chiyoda-ku , 100-86
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register